369 related articles for article (PubMed ID: 33827114)
21. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Jackson GH; Pawlyn C; Cairns DA; de Tute RM; Hockaday A; Collett C; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Rocci A; Snowden JA; Jenner MW; Cook G; Russell NH; Drayson MT; Gregory WM; Kaiser MF; Owen RG; Davies FE; Morgan GJ;
PLoS Med; 2021 Jan; 18(1):e1003454. PubMed ID: 33428632
[TBL] [Abstract][Full Text] [Related]
22. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Kazandjian D; Hill E; Dew A; Morrison C; Roswarski J; Korde N; Emanuel M; Petrosyan A; Bhutani M; Calvo KR; Dulau-Florea A; Kwok M; Lee MJ; Lee S; Lindenberg L; Mailankody S; Manasanch E; Maric I; Mena E; Patel N; Tageja N; Trepel JB; Turkbey B; Wang HW; Wang W; Yuan C; Zhang Y; Braylan R; Choyke P; Stetler-Stevenson M; Steinberg SM; Figg WD; Roschewski M; Landgren O
JAMA Oncol; 2021 Nov; 7(11):1678-1685. PubMed ID: 34529025
[TBL] [Abstract][Full Text] [Related]
23. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
Lee JH; Park Y; Kang KW; Lee JJ; Lee HS; Eom HS; Do YR; Kim JS; Yoon SS; Shin DY; Koh Y; Kim KH; Lee WS; Jo JC; Lee YJ; Lee JY; Kim DS; Shim H; Chang MH; Kim SH; Min CK;
Ann Hematol; 2021 Aug; 100(8):2051-2059. PubMed ID: 33447888
[TBL] [Abstract][Full Text] [Related]
24. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Jakubowiak A; Usmani SZ; Krishnan A; Lonial S; Comenzo RL; Wang J; de Boer C; Deraedt W; Weiss BM; Schecter JM; Chari A
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):701-710. PubMed ID: 34274290
[TBL] [Abstract][Full Text] [Related]
25. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Derman BA; Kansagra A; Zonder J; Stefka AT; Grinblatt DL; Anderson LD; Gurbuxani S; Narula S; Rayani S; Major A; Kin A; Jiang K; Karrison T; Jasielec J; Jakubowiak AJ
JAMA Oncol; 2022 Sep; 8(9):1278-1286. PubMed ID: 35862034
[TBL] [Abstract][Full Text] [Related]
26. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
27. Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
Mori Y; Takizawa J; Katsuoka Y; Takezako N; Nagafuji K; Handa H; Kuroda J; Sunami K; Kamimura T; Ogawa R; Kikushige Y; Harada M; Akashi K; Miyamoto T;
Cancer Sci; 2024 Jun; 115(6):2002-2011. PubMed ID: 38498976
[TBL] [Abstract][Full Text] [Related]
28. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Jakubowiak AJ; Dytfeld D; Griffith KA; Lebovic D; Vesole DH; Jagannath S; Al-Zoubi A; Anderson T; Nordgren B; Detweiler-Short K; Stockerl-Goldstein K; Ahmed A; Jobkar T; Durecki DE; McDonnell K; Mietzel M; Couriel D; Kaminski M; Vij R
Blood; 2012 Aug; 120(9):1801-9. PubMed ID: 22665938
[TBL] [Abstract][Full Text] [Related]
29. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Alsina M; Landgren O; Raje N; Niesvizky R; Bensinger WI; Berdeja JG; Kovacsovics T; Vesole DH; Fang B; Kimball AS; Siegel DS
Am J Hematol; 2021 Feb; 96(2):226-233. PubMed ID: 33125764
[TBL] [Abstract][Full Text] [Related]
30. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
31. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall A; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
J Clin Oncol; 2022 Sep; 40(25):2901-2912. PubMed ID: 34898239
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis.
Costa BA; Costa TA; Pak K; Patel A; Felix N; Mouhieddine TH; Richter J
Am J Hematol; 2024 Jul; 99(7):1411-1414. PubMed ID: 38606993
[TBL] [Abstract][Full Text] [Related]
33. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
van de Donk NWCJ; Minnema MC; van der Holt B; Schjesvold F; Wu KL; Broijl A; Roeloffzen WWH; Gadisseur A; Pietrantuono G; Pour L; van der Velden VHJ; Lund T; Offidani M; Grasso M; Giaccone L; Razawy W; Tacchetti P; Mancuso K; Silkjaer T; Caers J; Zweegman S; Hájek R; Benjamin R; Vangsted AJ; Boccadoro M; Gay F; Sonneveld P; Musto P
Lancet Oncol; 2023 Oct; 24(10):1119-1133. PubMed ID: 37717583
[TBL] [Abstract][Full Text] [Related]
34. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
Sonneveld P; Dimopoulos MA; Beksac M; van der Holt B; Aquino S; Ludwig H; Zweegman S; Zander T; Zamagni E; Wester R; Hajek R; Pantani L; Dozza L; Gay F; Cafro A; De Rosa L; Morelli A; Gregersen H; Gulbrandsen N; Cornelisse P; Troia R; Oliva S; van de Velden V; Wu K; Ypma PF; Bos G; Levin MD; Pour L; Driessen C; Broijl A; Croockewit A; Minnema MC; Waage A; Hveding C; van de Donk NWCJ; Offidani M; Palumbo GA; Spencer A; Boccadoro M; Cavo M
J Clin Oncol; 2021 Nov; 39(32):3613-3622. PubMed ID: 34520219
[TBL] [Abstract][Full Text] [Related]
35. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
Derman BA; Cooperrider J; Rosenblatt J; Avigan DE; Rampurwala M; Barnidge D; Major A; Karrison T; Jiang K; Ramsland A; Kubicki T; Jakubowiak AJ
Blood Cancer J; 2024 May; 14(1):87. PubMed ID: 38811560
[TBL] [Abstract][Full Text] [Related]
36. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.
Sugiura I; Suzuki K; Ri M; Chou T; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Iida S
Int J Hematol; 2020 Jan; 111(1):57-64. PubMed ID: 31664647
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
[TBL] [Abstract][Full Text] [Related]
38. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S; Tacchetti P; Pantani L; Mancuso K; Rizzello I; di Giovanni Bezzi C; Scalese M; Dozza L; Marzocchi G; Martello M; Barilà G; Antonioli E; Staderini M; Buda G; Petrini M; Cea M; Quaresima M; Furlan A; Bonalumi A; Cavo M; Zamagni E
Hematol Oncol; 2021 Feb; 39(1):41-50. PubMed ID: 33085797
[TBL] [Abstract][Full Text] [Related]
39. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
Suzuki K; Ri M; Chou T; Sugiura I; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Ota K; Iida S
Cancer Sci; 2017 Mar; 108(3):461-468. PubMed ID: 28092421
[TBL] [Abstract][Full Text] [Related]
40. Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
Yoroidaka T; Yamashita T; Murata R; Yoshihara K; Yoshihara S; Ueda M; Nakao S; Matsue K; Takamatsu H
Anticancer Res; 2023 Jan; 43(1):157-165. PubMed ID: 36585165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
